This site is intended for healthcare professionals

Seres Therapeutics and Nestle Health Science to jointly commercialise SER 109 ,oral microbiome, in United States and Canada.

Read time: 1 mins
Last updated:29th Jul 2021
Published:2nd Jul 2021
Seres Therapeutics, Inc. announced that it has entered into an agreement with Nestlé Health Science to jointly commercialize SER 109, Seres’ investigational oral microbiome therapeutic for recurrent Clostridioides difficile infection (CDI), in the United States and Canada. If approved, SER-109 would become the first-ever FDA-approved microbiome therapeutic.
Condition: Infectious Diseases/Clostridium
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest